Clinical Trial

Tezspire Cardiac Events PASS

Study acronym: TRESPASS
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-04-23; most recent amendment 2026-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-11-04
Trial Details
NCT Number NCT06951867
Lead Sponsor AstraZeneca
Collaborators: IQVIA Pvt. Ltd
Conditions Cardiovascular Events, MACE
Enrollment 16,640 participants
Start Date 2025-09-15
Primary Completion 2029-05-31 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-27